How can the EU’s pharmaceutical legislation help tackle current challenges, including medicine shortages and antimicrobial resistance, across Europe? We put the question to Rainer Becker, Director for Medical Products and Innovation at DG SANTE.
Jay Sibbitts, Shu Jia, Obdulia Covarrubias-Zambrano, Stefan H. Bossmann and Christopher T Culbertson from Kansas State University’s Department of Chemistry walk us through what we need to know about microfluidic devices for detecting pain.
Scientists at TCS designed novel chemical compounds using AI that can inhibit the 3CL protease of SARS-CoV-2, which is responsible for viral replication. Ananth Krishnan, Chief Technology Office, TCS, discusses the research here.
Several drugs used for curing hepatitis C have been identified as potential candidates to treat COVID-19, according to research conducted using the MOGON II supercomputer at Johannes Gutenberg University Mainz.
Liam McGreevy, CEO of Ethnopharm Ltd, explains his thoughts on creating value in today’s maturing cannabis market, including how the firm can help both new and established businesses make sense of this.
Cannabis (hemp) contains up to 150 different terpenes. They not only determine the smell, but they also have valuable properties for the body as studies show. Katharina Zedlacher, from BioBloom GmbH, discusses the effect of terpenes in CBD full extracts.
Dr Vincent Maida discusses his discoveries and pioneering research in the area of using Topical Cannabis-Based Medicines (TCBM) for integumentary and wound management.
Peter Jackson, Executive Director of the AMR Centre, describes new initiatives and partnerships that point the way forward for the UK’s antimicrobial resistance response.
Prof Colin J Suckling OBE DSc FRSE from the Department of Pure & Applied Chemistry, details the ‘why’ and ‘what’ of academic drug discovery research at the University of Strathclyde, as well as his thoughts on the value of a chemistry degree.
With attention turning in the U.S. and elsewhere to how cannabis businesses are banked, John Binns, Partner at BCL Solicitors LLP, gets into the weeds of how UK banks have been addressing the issue, as well as the prospects for improvement.
